← Compound index
COMPOUND RECORD / TIREOGEN

TireogenТиреоген

A peptide mixture extracted from young animal thyroid glands, described in a Russian report on thyroid hormones.

Source linked

What the studies found

Comparison in people · 2017

Tireogen and Endoluten as adjuncts in autoimmune thyroiditis

Study of multiple preparations

TSH at month four
Standard care 7.14 ± 0.86, Tireogen 4.09 ± 0.12, combination 3.94 ± 0.12 mIU/L. Shared baseline 8.84 ± 1.09.The table marks both adjunctive arms as significantly different from standard care.
Anti-thyroglobulin antibodies
83.32 ± 3.28, 77.41 ± 1.18 and 18.91 ± 1.65 IU/L in the three groups, respectively.The table marks both adjunctive arms. The narrative describes no antibody effect with Tireogen alone.
Anti-thyroid peroxidase antibodies
361.24 ± 12.4, 357.23 ± 11.41 and 29.16 ± 2.54 IU/L, respectively. The table gives no significance mark for this row.

At four months the author table reports TSH of 7.14 with standard care, 4.09 with adjunctive Tireogen, and 3.94 mIU/L with the combination. Antibody findings are reported with inconsistencies between table and narrative.

Study notes · methods, sources and limitations

Participants or model 218 adults aged 39–51: 89 standard treatment, 42 standard treatment plus Tireogen, 87 standard treatment plus Tireogen and Endoluten.

Design 89 patients received standard treatment, 42 added Tireogen and 87 added Tireogen plus Endoluten. The reported schedules were two Tireogen capsules daily and one Endoluten capsule every three days for four months. Capsule mass is unspecified. The levothyroxine unit in the reproduction is anomalous.

Important limitations

  • Allocation, masking and separate baseline values are unspecified. There was no Endoluten-only arm. The table marks an anti-thyroglobulin difference for Tireogen alone, while the narrative says Tireogen alone did not affect antibodies. The anti-TPO row gives no significance mark. The reproduction prints an anomalous levothyroxine unit. The exact background dose is uncertain.
  • The authors credit the St. Petersburg Institute of Bioregulation and Gerontology with developing both preparations. The study took place at the Centre for Revitalization and Health in Moscow. The design leaves allocation unspecified and the table gives one shared baseline.

Innovation in Aging. 2017;1(Suppl 1):324. PMCID PMC6243877. · Published conference abstract with author report

Original source or citation ↗

Source for the reported results ↗

Study results and tables ↗

Comparison in people · 2006

Tireogen: institute clinical report (commercially hosted translation)

The report describes symptom and thyroid-hormone changes during adjunctive care.

Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology

Study notes · methods, sources and limitations

Participants or model 25 treated patients and 19 controls with primary hypothyroidism; report dates November 2005–January 2006

Important limitations

  • Commercial reproduction: signed original, protocol and translation accuracy have not been authenticated. Concurrent thyroid treatment is inadequately specified. This cannot establish a substitute for thyroid-hormone replacement or confirm durable thyroid restoration. Short follow-up and incomplete adverse-event methods do not establish safety; independent replication and present-day product equivalence remain unverified.

Institute-attributed report, 2006; commercially hosted brochure pp. 73–74 · Institute report — commercial reproduction

Original source or citation ↗

Study results and tables ↗
01 / OVERVIEW

About Tireogen

Identity / background source ↗

Research background

Tireogen is a thyroid-associated peptide preparation. A Medical Center report followed thyroid markers in primary hypothyroidism. A separate 218-person comparison evaluated Tireogen with and without Endoluten in autoimmune thyroiditis.

Compound class
Archival preparation lead
Research collection
Peptide bioregulation · editorial grouping
Institutions in linked studies
Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

25 treated patients and 19 controls with primary hypothyroidism; report dates November 2005–January 2006

Study methods

Small adjunctive comparison; signed original, allocation and reporting require verification

Independent replication

New citations are not automatically independent replication; shared programs and translated reports require cohort checks

Source access

New indexed primary abstracts and/or report reproductions linked; review depth shown per source

Safety evidence

Reported tolerability is not proof of safety; uncommon harms and long-term outcomes remain unresolved

Open a topic for the evidence assessment.

More findings, background and history

What remains unclear

The original report and protocol would clarify group sizes, background treatment and translation. Independent replication and equivalence to current products remain uncertain.

Human reports are linked; their presence does not establish effectiveness. Several publications can describe the same participants.

Browse original study records ↗

Explore the expanded peptide research collection and unresolved source trails ↗

View this preparation in the Khavinson evidence map ↗

03 / SOURCE RECORDS

Findings by study

Tissue-preparation reports: comparisons, source limits and remaining gaps ↗

Explore related research ↗

Comparison in people · 2017

Tireogen and Endoluten as adjuncts in autoimmune thyroiditis

At four months the author table reports TSH of 7.14 with standard care, 4.09 with adjunctive Tireogen, and 3.94 mIU/L with the combination. Antibody findings are reported with inconsistencies between table and narrative.

Study notes and original source
2017Human comparative studyEnglish abstract

Tireogen and Endoluten as adjuncts in autoimmune thyroiditis

Oral Tireogen, or Tireogen plus Endoluten, alongside standard treatment · Published conference abstract with author report

D. A. Gorgiladze, R. N. Pinaev, V. A. Aleksandrov · Innovation in Aging. 2017;1(Suppl 1):324. PMCID PMC6243877.

At four months the author table reports TSH of 7.14 with standard care, 4.09 with adjunctive Tireogen, and 3.94 mIU/L with the combination. Antibody findings are reported with inconsistencies between table and narrative.

Results and tables

Reported findings and study design

89 patients received standard treatment, 42 added Tireogen and 87 added Tireogen plus Endoluten. The reported schedules were two Tireogen capsules daily and one Endoluten capsule every three days for four months. Capsule mass is unspecified. The levothyroxine unit in the reproduction is anomalous.

Population or model 218 adults aged 39–51: 89 standard treatment, 42 standard treatment plus Tireogen, 87 standard treatment plus Tireogen and Endoluten.

Results · Authors’ conference report reproduction, methods and Table 1, matched to the published abstract
MeasureResultComparison, timing and statistics
TSH at month fourStandard care 7.14 ± 0.86, Tireogen 4.09 ± 0.12, combination 3.94 ± 0.12 mIU/L. Shared baseline 8.84 ± 1.09.The table marks both adjunctive arms as significantly different from standard care.
Anti-thyroglobulin antibodies83.32 ± 3.28, 77.41 ± 1.18 and 18.91 ± 1.65 IU/L in the three groups, respectively.The table marks both adjunctive arms. The narrative describes no antibody effect with Tireogen alone.
Anti-thyroid peroxidase antibodies361.24 ± 12.4, 357.23 ± 11.41 and 29.16 ± 2.54 IU/L, respectively. The table gives no significance mark for this row.

The authors credit the St. Petersburg Institute of Bioregulation and Gerontology with developing both preparations. The study took place at the Centre for Revitalization and Health in Moscow. The design leaves allocation unspecified and the table gives one shared baseline.

Source for these results ↗ · Reviewed 2026-11-16

Population / setting
218 adults aged 39–51: 89 standard treatment, 42 standard treatment plus Tireogen, 87 standard treatment plus Tireogen and Endoluten.
Source reviewed
Published 2017 conference abstract and authors’ reproduced report, PDF pages 16–17. The 2015 and 2017 presentations describe the same study program.
Study limitations
  • Allocation, masking and separate baseline values are unspecified. There was no Endoluten-only arm.
  • The table marks an anti-thyroglobulin difference for Tireogen alone, while the narrative says Tireogen alone did not affect antibodies. The anti-TPO row gives no significance mark.
  • The reproduction prints an anomalous levothyroxine unit. The exact background dose is uncertain.

Reviewed 2026-11-16.

Read the source ↗

Comparison in people · 2006

Tireogen: institute clinical report (commercially hosted translation)

The report describes symptom and thyroid-hormone changes during adjunctive care.

Study notes and original source
2006Human comparative studyFull text available

Tireogen: institute clinical report (commercially hosted translation)

Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology

Tissue-derived mixture / named preparation · Institute report — commercial reproduction

Format: PDF · Reviewed: Report reproduction reviewed

St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute-attributed report, 2006; commercially hosted brochure pp. 73–74

The report describes symptom and thyroid-hormone changes during adjunctive care.

Population / setting
25 treated patients and 19 controls with primary hypothyroidism; report dates November 2005–January 2006
Source reviewed
Brochure PDF pp. 73–74: methods/results text checked; selected population/table pages visually inspected. This is a provenance check, not authentication of the institute original.
Study limitations
  • Commercial reproduction: signed original, protocol and translation accuracy have not been authenticated.
  • Concurrent thyroid treatment is inadequately specified. This cannot establish a substitute for thyroid-hormone replacement or confirm durable thyroid restoration.
  • Short follow-up and incomplete adverse-event methods do not establish safety; independent replication and present-day product equivalence remain unverified.

Reviewed 2026-10-05.

Read the source ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗